A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

BACKGROUND: Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. OBJECTIVE: Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban. METHODS: In this ra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Pharmacol
Hauptverfasser: Frost, Charles, Song, Yan, Barrett, Yu Chen, Wang, Jessie, Pursley, Janice, Boyd, Rebecca A, LaCreta, Frank
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2014
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4235474/
https://ncbi.nlm.nih.gov/pubmed/25419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S61131
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge